Clinical Trial Update: Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali [NA]

View source ↗

Summary

A clinical trial comparing misoprostol and oxytocin in Uniject for postpartum hemorrhage prevention in Mali has been withdrawn from enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Hemorrhage

Drugs mentioned

• MISOPROSTOL (Misoprostol)
• Oxytocin (Oxytocin)

Snippet

Sponsor: Gynuity Health Projects | Conditions: Postpartum Hemorrhage | NA | Status: WITHDRAWN